We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
from PART IV - PHARMOLOGY
Published online by Cambridge University Press: 10 May 2010
“At that time two men will be working in a field:
one will be taken away, the other will be left behind.
Two women will be at a mill grinding meal:
one will be taken away, the other will be left behind.”
Mt. 24, 40–41Antiplatelet strategy: a brief historical review
The first three drugs tested in clinical trials for their potential antiplatelet effects were all already used in current practice for different reasons, unrelated to thrombosis and ischemic artery disease.
Aspirin was known as an anti-inflammatory compound, sulfinpyrazone was used for its uricosuric properties and dipyridamole was endowed with vasodilatory (coronarodilatory) effect. Their mechanism of action, as antiplatelet agents, was largely unknown, but the possibility of replacing oral anticoagulants with relatively safer substances, not requiring any laboratory control, convinced many clinicians to adapt an antiplatelet strategy, even before the results of well-planned and conducted clinical trials were made available.
The discovery of the crucial role of prostaglandins and thromboxane A2 (TxA2) in platelet function and of their possibly unselective pharmacological control by aspirin, stimulated for the first time the search for a more rational antiplatelet strategy.
However, the development of selective TxA2-synthase inhibitors, TxA2-receptor antagonists and of compounds endowed with both properties was not followed by the expected clinical results. This was due to several reasons, including the complex re-orientation of platelet arachidonate metabolism following pharmacological suppression of TxA2 synthesis or of its receptor function.
To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Find out more about the Kindle Personal Document Service.
To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.
To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.
